by Meriem Bouslouk-Marx | 27 May 2024
Obstacles for patient access to medicines can happen at different stages of a medicine’s life cycle. Therefore, marketing authorisation should not be the ultimate goal. Patient, regulatory and HTA perspectives on an EU approved orphan drug were discussed at the... by Meriem Bouslouk-Marx | 6 Oct 2023
The global community of market access professionals met in France on 2 October 2023 at the Market Access Day Paris 2023 – the first post-pandemic event of the Market Access Society (MAS). This meeting was also a great opportunity to discuss the latest developments of... by Meriem Bouslouk-Marx | 7 Sep 2023
The G-BA Office in Berlin, Germany After Boehringer Ingelheim’s announcement to withdraw a medicine for the treatment of a rare skin disease from the German market on 29 August 2023, a heated debate has erupted on the benefit assessment of new therapies in Germany.... by Meriem Bouslouk-Marx | 17 Apr 2023
Do you know IMAS? If you are a professional in Market Access who believes that your education and training are crucial for patient access to relevant therapies, then you should! IMAS stands for International Market Access Society. It derives from MAS, the Market... by Meriem Bouslouk-Marx | 28 Feb 2023
I remember very well the day I asked the G-BA for permission to speak about the specific German benefit assessment of orphan drugs. Although I used to represent the G-BA and AMNOG internationally, I did not dare to give a talk solely on orphan drugs. Why? Because I... by Meriem Bouslouk-Marx | 14 Feb 2023
The G-BA took the opportunity to announce its work programme for 2023 at a press conference on 14 February 2023. The impartial G-BA Chair professor Josef Hecken highlighted in his introduction speech that the G-BA had made over 1,000 benefit assessment decisions since...